San Diego-based biotech Receptos has priced an initial public offering of 5.2 million shares at $14, raising $72.8 million as the company closes in on late-stage development of its lead candidate for multiple sclerosis.
Using MRI scans to measure tissue atrophy in the thalamus can accurately predict multiple sclerosis, according to new research, pointing the way to a more reliable biomarker than current methods.
Biogen Idec's new multiple sclerosis pill made its debut to high expectations earlier this month. And so far, Tecfidera hasn't disappointed. As The Street reports, the drug has literally leapt onto the market. Its first week's worth of prescriptions surpassed 300, a rate that Novartis' first-to-market rival didn't hit until almost three months after launch.
Scientists at Cleveland's Case Western Reserve School of Medicine have developed a technique in mice that converts skin cells to the kind of brain cells that get damaged in diseases like multiple sclerosis, cerebral palsy and other so-called myelin disorders.
Shares of Biogen Idec ($BIIB) surged to around the $197 mark this morning as the company detailed data on its promising Phase IIb study of the multiple sclerosis drug daclizumab.
Novartis is thinking young. The Swiss drugmaker is using a cheeky ad campaign, targeted at 20- and 30-somethings not only in magazines, but via websites and social media. Novartis needs to find a new edge in the MS market, where it faces not only well-established injectable drugs, but two new oral rivals.
Biogen Idec's recently approved Tecfidera, a blockbuster oral treatment for multiple sclerosis, is set to hit pharmacies this week, filling the need for a safe and effective option for patients with the disease.
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.
The FDA gave its final blessing to Biogen Idec's much-anticipated multiple sclerosis pill Tecfidera. It's the third oral MS treatment to hit a market long limited to injectable drugs. But Biogen believes--and many analysts agree--that Tecfidera can surpass its oral competitors, and quickly.
Biogen Idec seized U.S. approval for its new oral multiple sclerosis drug, Tecfidera, already touted as a sure blockbuster.